伊普塔科潘在患有C3型淋巴细胞病变的患者中的有效性和安全性
Edwin Wong1,2, Carla Nester3, Teresa Cavero4
1National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.
Kidney international reports
|December 18, 2023
概括
伊普塔科潘显著降低了C3球粒细胞病变中的蛋白尿和移植中的补充沉积. 这项研究表明,伊普塔科潘是一种有前途的向疗法,用于罕见的补充介导脏疾病.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 补 3 球囊病 (C3G) 是一种罕见的,激进的病,由替代补途径失调驱动.
- 目前,C3G没有针对性的治疗方法,因此需要研究新的治疗方案.
研究的目的:
- 评估伊普塔科潘在C3G患者中的疗效,安全性,耐受性,药理动力学和药理动力学.
- 评估伊普塔科潘对关键补充生物标志物的影响,以及本土和移植接受者的临床结果.
主要方法:
- 第二阶段,多中心,开放标签,单臂研究,对27名成年患者进行了活检证明的C3G.
- 患者在剂量调整后,每天两次接受iptacopan,持续84天.
- 主要终点包括原生队列中的尿蛋白与肌素比率 (UPCR) 和移植队列中的C3沉积积分.
主要成果:
- 在本地C3G队列中,UPCR显著减少45% (P=0.0003).
- 在C3G复发的移植患者中降低了C3沉积分 (P=0.03).
- 大多数患者的血清C3水平达到正常,这表明补体活性过度减少.
结论:
- 伊普塔科潘在统计学上显著,在临床上有意义的减少蛋白尿和补充沉积.
- 该药物在患有C3G.的患者中表现出良好的安全性和耐受性概况.
- 伊普塔科潘代表了对C3G和相关的补充介导脏疾病的潜在向治疗选择.
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
187
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
187
01:27Open Angle Glaucoma: Treatment
455
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
455
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
142
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
142
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
174
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
174
01:28Angle Closure Glaucoma: Treatment
514
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
514